THC provides modest but real relief for some types of neuropathic pain, though the benefit is smaller and less consistent than many patients expect. When all cannabis-based medicines are pooled together, roughly 39% of people in clinical trials achieved at least a 30% drop in pain compared with 33% on placebo. That gap is statistically meaningful but narrow, and the quality of evidence ranges from low to moderate depending on the outcome measured. The picture also shifts depending on what kind of nerve pain you have, how THC is delivered, and whether it is combined with CBD.
What the Largest Reviews Actually Show
The most comprehensive look at this question comes from Cochrane systematic reviews, which pool data across multiple randomized trials. An earlier Cochrane review covering over 1,500 participants found that cannabis-based medicines (including THC-dominant products, THC/CBD combinations, and synthetic cannabinoids) probably increase the number of people achieving at least 30% pain relief compared with placebo, with about 11 people needing to be treated for one additional person to benefit.1PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults For the higher bar of 50% pain relief, about 21% of people on cannabis-based medicines reached it compared with 17% on placebo, a difference that was barely significant.
An updated Cochrane review sharpened the lens by separating out THC-dominant medicines specifically. The results were more discouraging: when only THC-dominant products were analyzed, there was “no clear evidence” of benefit for 50% or 30% pain relief, with very low certainty across seven studies covering more than 500 participants.2PubMed. Cannabis-based medicines for chronic neuropathic pain in adults That does not mean THC definitely fails. It means the trials available were too small, too variable, or too poorly designed to draw confident conclusions. The uncertainty itself is the finding. Meanwhile, the updated review also confirmed that THC-dominant medicines likely increase nervous system side effects like dizziness and drowsiness.
Peripheral Nerve Pain From Diabetes
Diabetic peripheral neuropathy is one of the most common and stubborn forms of nerve pain, and a handful of small trials have tested inhaled cannabis specifically for it. In a randomized, double-blinded crossover study of 16 patients with painful diabetic neuropathy who had not responded well to other treatments, inhaled cannabis at three THC concentrations (1%, 4%, and 7%) all reduced spontaneous pain compared with placebo, with higher doses producing greater relief.3PubMed Central. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy The effect was dose-dependent and statistically significant even at the lowest dose.
A secondary analysis of that same trial uncovered something surprising about the dose-response curve. Pain relief did not keep climbing as THC blood levels rose. Instead, the relationship was U-shaped: pain was worst at both very low and very high plasma THC levels, with the sweet spot falling between roughly 16 and 31 nanograms per milliliter.4PubMed. A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy In other words, more THC is not necessarily better, and overshooting the dose can actually worsen pain perception. This is a critical insight for anyone experimenting with THC for nerve pain, because the impulse to increase the dose when pain persists may be counterproductive.
HIV-Associated Neuropathy
Some of the most cited evidence for THC and nerve pain comes from trials in people with HIV-associated sensory neuropathy, a painful condition affecting the feet and legs. Two well-designed randomized controlled trials tested smoked cannabis in this population, and both found significant benefit. In one crossover trial, pain reduction was substantially greater during the cannabis week than the placebo week, with about 46% of participants achieving at least 30% pain relief on cannabis compared with 18% on placebo.5PubMed Central. Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial
The second trial reported similar numbers: smoked cannabis reduced daily pain by about 34% (median) compared with 17% for placebo, and 52% of the cannabis group reported at least a 30% pain reduction versus 24% in the placebo group.6PubMed. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial These are among the more convincing trial results in the neuropathic pain space, though both studies were small (28 and 50 participants, respectively). The consistency between them, conducted by different research groups, strengthens the signal.
Central Neuropathic Pain in Multiple Sclerosis
Neuropathic pain in multiple sclerosis arises from damage within the central nervous system itself rather than peripheral nerves, and it responds poorly to many standard painkillers. Sativex, an oromucosal spray delivering a roughly 1:1 ratio of THC to CBD, has been studied more extensively in this population than in most other neuropathic pain groups. A randomized controlled trial of 66 MS patients found that Sativex significantly reduced pain scores compared with placebo and also improved sleep disturbance.7The Journal of Pain. The efficacy and tolerability of a cannabis-based medicine in central pain secondary to multiple sclerosis
A more recent systematic review and meta-analysis pooling data from multiple Sativex trials in MS found a significant reduction in pain intensity along with meaningful improvements in spasticity and a modest improvement in disability scores.8PubMed. Efficacy of Sativex® on pain, spasticity, and disability in patients with multiple sclerosis: A systematic review and meta-analysis Another study using neurophysiological measurements found that Sativex not only reduced pain ratings but also changed brain oscillation patterns associated with pain processing, suggesting the drug was acting on specific cortical pathways rather than simply sedating patients.9PubMed. Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis The MS evidence is probably the strongest case for cannabis-based medicines in any neuropathic pain condition, partly because Sativex has gone through more rigorous regulatory scrutiny than most cannabis products.
Chemotherapy-Induced Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a frustrating condition because it often persists long after cancer treatment ends, and few drugs reliably treat it. The human evidence for THC here is thin. A case series of cancer patients using topical cannabinoids found that some reported improvement in pain, burning, or tingling that had not responded to other treatments, but the benefit wore off within hours, requiring repeated application.10PubMed Central. Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series
Preclinical work in mice tells a more interesting story. Both THC and CBD individually reduced mechanical pain sensitivity caused by the chemotherapy drug paclitaxel. When very low doses of each were combined, the effect was synergistic, meaning the combination worked better than either alone at doses that had no effect individually. Interestingly, the two cannabinoids responded differently to different chemotherapy agents: CBD helped with oxaliplatin-induced pain but not vincristine-induced pain, while THC showed the opposite pattern.11PubMed Central. Single and combined effects of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain If this selectivity translates to humans, it could mean that the “right” cannabinoid depends on which chemotherapy drug caused the neuropathy. But we are a long way from confirming that in patients.
Why Lower Doses Often Work Better
One of the most counterintuitive findings in this area is that low-dose THC can be just as effective as higher doses for nerve pain, with far fewer side effects. A trial of 39 patients with central and peripheral neuropathic pain compared vaporized cannabis at 1.29% THC, 3.53% THC, and placebo. Both active doses produced significant pain relief, with no meaningful difference between them. The number needed to treat for 30% pain reduction was about 3 for both doses compared with placebo, which is comparable to standard neuropathic pain medications like gabapentin or duloxetine.12PubMed Central. Low-dose vaporized cannabis significantly improves neuropathic pain Psychoactive effects at the low dose were minimal, and any cognitive changes reversed within one to two hours.
The U-shaped dose-response curve seen in the diabetic neuropathy trial mentioned earlier reinforces this finding. Once you pass a certain blood level of THC, pain relief plateaus and then declines, while side effects continue to climb. This creates a practical problem: without blood monitoring, patients using smoked or vaporized cannabis cannot easily know their plasma THC level. The takeaway is directional rather than precise: start low, and resist the urge to escalate quickly if the first dose doesn’t seem strong enough.
THC Alone Versus THC Combined With CBD
Whether adding CBD to THC makes a difference for nerve pain is a genuinely open question, and the data pull in different directions. A meta-analysis of cannabis-based medicines for neuropathic pain found that both THC alone and THC/CBD combinations produced significant reductions in pain intensity compared with placebo, while CBD by itself did not show a significant effect.13PubMed Central. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis The combination appeared slightly more effective than THC alone for some outcomes, though the confidence intervals overlapped enough to make firm conclusions difficult.
A more recent trial directly compared oral capsules of THC alone, CBD alone, and a THC/CBD combination for peripheral neuropathic pain. After eight weeks, the THC/CBD combination showed a small improvement over placebo, while CBD alone actually performed worse than placebo, and THC alone fell somewhere in between.14PubMed. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment The effect sizes were modest across the board. The mouse data on chemotherapy neuropathy, where very low doses of THC and CBD together outperformed either one alone, hints at synergy that has not been reliably replicated in human neuropathic pain trials. For now, combination products appear at least as good as THC alone and may offer a slight edge, but the case for synergy in humans remains unproven.
Sleep and Quality of Life
Even when pain relief itself is modest, cannabis-based medicines consistently improve sleep in neuropathic pain trials. The Cochrane review found that cannabis-based medicines were better than placebo at reducing sleep problems and psychological distress alongside pain intensity.15PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults – Section: Abstract A trial of smoked cannabis in neuropathic pain found that participants using 9.4% THC cannabis reported falling asleep more easily, falling asleep faster, and waking less often during the night compared with placebo.16CMAJ. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
Long-term data from Sativex safety extension studies lasting up to four years found that 40 to 50% of participants achieved good or very good sleep quality, with no sign of tolerance developing over that period.17PubMed. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine That last point matters: CBD appears to have a mild activating effect, while THC-predominant products lean toward sedation. For people with neuropathic pain whose sleep is severely disrupted by nighttime pain, the sleep benefit alone can meaningfully improve quality of life even if the analgesic effect is incomplete.
Side Effects Worth Knowing About
The most common side effects in neuropathic pain trials are nervous system effects: dizziness, drowsiness, difficulty concentrating, and feeling “high.” The earlier Cochrane review found that roughly 61% of people using cannabis-based medicines reported nervous system adverse events compared with 29% on placebo.18PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults – Section: Main results About twice as many people dropped out of studies due to side effects on the active drug versus placebo (10% vs. 5%). These are not rare or trivial effects, and they weigh heavily when the pain benefit is modest.
A survey of patients using medical cannabis for chronic musculoskeletal pain found that about 72% reported no noticeable effect on their thinking or coordination. Around 12% reported worse cognition but still felt their symptoms improved, while about 13% reported worse thinking with no symptom benefit.19PubMed Central. Patterns, Efficacy, and Cognitive Effects of Medical Cannabis Use in Chronic Musculoskeletal Pain Patients Long-term cannabis use does carry concerns about memory and executive function, with effects that appear more pronounced in people who start younger and use chronically.20PubMed Central. Adverse Effects of Recreational and Medical Cannabis
Synthetic cannabinoids like dronabinol and nabilone, sometimes prescribed for pain, carry their own side-effect profiles. Nabilone produces drowsiness at more than seven times the rate of placebo, and dizziness at more than 20 times the rate. Dronabinol causes dry mouth about five times more often than placebo and dizziness about four and a half times more often.21PubMed Central. The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials These numbers come from a meta-analysis of clinical trial data and highlight that synthetic versions are not necessarily “cleaner” alternatives.
The Opioid-Sparing Question
One of the most appealing arguments for cannabinoids in neuropathic pain is the possibility that they could reduce opioid use. Preclinical studies are encouraging: a meta-analysis of animal studies found that the effective dose of morphine dropped by a factor of roughly 3.6 when combined with THC.22PubMed Central. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis Observational studies in humans align with this: an updated meta-analysis found that about 39% of people using cannabinoids reported stopping opioids entirely, and 85% reported reducing their dose.23Neuropsychopharmacology. Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies
The catch is that these observational findings have not held up in the higher-quality randomized controlled trials conducted so far. The same updated meta-analysis noted this disconnect explicitly: preclinical and observational data support opioid-sparing effects, but the RCTs available do not confirm them. This gap could mean the observational studies are picking up placebo effects or self-selection bias (people who do well on cannabis are more likely to report cutting back on opioids), or it could mean the RCTs have been too small or too short to detect a real effect. Either way, calling THC a proven opioid substitute goes beyond what the controlled evidence supports right now.
Long-Term Use and Tolerance
A common concern with any pain medication is whether tolerance develops, requiring escalating doses over time. An open-label follow-up study of patients using THC/CBD oromucosal spray for neuropathic pain tracked outcomes over extended periods. Pain scores dropped from an average of about 6.9 at baseline to 4.2 by the end of follow-up, and the proportion of patients reporting at least 30% improvement continued to increase over the first nine months rather than fading.24SpringerLink / Journal of Neurology. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain Patients did not seek to increase their dose over time, and no new safety concerns emerged. The four-year Sativex extension data on sleep mentioned earlier echoed this: no tolerance to the sleep benefit was observed either.
Open-label follow-up studies are inherently less rigorous than blinded trials, because patients who stay in them are usually those benefiting. People who do poorly tend to drop out. So while these results are reassuring about tolerance, they overstate the overall response rate. Still, the absence of dose escalation in those who continued treatment is noteworthy, because it runs counter to patterns seen with opioids and some other pain medications.
How Biology Shapes Individual Responses
One of the most frustrating aspects of THC for neuropathic pain is the wide variability in who responds. Some people get meaningful relief; many do not. Part of this likely traces to genetic differences in the endocannabinoid system itself. Research has linked genetic variations in the FAAH gene, which encodes the enzyme that breaks down the body’s own endocannabinoids, to differences in pain sensitivity and the tendency for pain to become chronic.25PubMed Central. Contribution of Endocannabinoid Gene Expression and Genotype on Low Back Pain Susceptibility and Chronicity If your body naturally clears endocannabinoids faster or slower, supplementing with external THC may have very different effects.
At the spinal cord level, nerve injury triggers changes in cannabinoid receptor expression. Animal studies have shown that after peripheral nerve damage, CB2 receptors become more concentrated on immune cells in the spinal cord called microglia. Activating these receptors reduced pain-related hypersensitivity in a dose-dependent way without producing tolerance.26PubMed Central. Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury This suggests the cannabinoid system is actively remodeled by nerve damage, which could partly explain why THC helps some neuropathic pain conditions more than others and why individual responses differ even within the same diagnosis.
Older Adults and Special Considerations
Neuropathic pain becomes more common with age, driven by rising rates of diabetes, post-surgical nerve damage, and conditions like shingles. Older adults face particular challenges with cannabis-based medicines because they metabolize THC more slowly, tend to be more sensitive to psychoactive effects, and often take multiple other medications that could interact. Balance and fall risk are also real concerns when dizziness and drowsiness are among the most common side effects. Most neuropathic pain trials have enrolled younger or middle-aged adults, so the evidence base for people over 65 is slim. Clinicians working with older patients generally recommend starting at the lowest available dose and increasing very gradually, but high-quality trial data to guide those decisions are largely missing.
Age aside, people with a personal or family history of psychosis, schizophrenia, or bipolar disorder face elevated risks from THC. Cannabis use can trigger or worsen psychotic symptoms in vulnerable individuals, a risk that does not disappear just because the product is labeled “medical.” Anyone considering THC for neuropathic pain who falls into a higher-risk psychiatric category should weigh that carefully with a physician who knows their full history.